CReATe Consortium

CReATe Podcast

Health EN ↓ 89 episodes

CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.

Be sure to visit the podcast's website and support the creator: www.spreaker.com

Author

CReATe Consortium

Category

Health

Podcast website

www.spreaker.com

Latest episode

Sep 22, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

CReATe Author Series Ep. 20 - Dr. Michael Benatar and Proteomics of Pre-symptomatic ALS 22.09.2026

Dr. Michael Benatar is a professor of neurology and chief of the Neuromuscular Division and executive director of the ALS Center at the University of Miami. Here he discusses the recent publication “Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS". 

ALS Untangled Series Ep. 68 - Pyridostigmine 03.09.2026

Pyridostigmine enhances neuromuscular transmission and is commonly used to treat myasthenia gravis. The effect of pyridostigmine in slowing ALS progression is uncertain. Here we discuss the potential mechanisms, cases, clinical trial data, and potential risks. 

ALS Untangled Series Ep. 67 - Alpha Lipoic Acid 07.08.2026

Alpha-lipoic acid (ALA) is a naturally occurring fatty acid. It has several plausible mechanisms for slowing ALS progression. Preclinical studies showed ALA slowed motor function decline. Some patients reported improvement when taking ALA together with other supplements. Here we discuss the mechanism, clinical studies, and potential risks. 

CReATe Author Series Ep. 19 - Dr. Paul Lingor on Fasudil as a Potential Therapeutic for ALS 01.07.2026

Paul Lingor, MD, is Professor for Neurology, Group Leader and Head of the Outpatient Clinics for Motoneuron Disorders and Co-head of the Outpatient Clinics for Movement Disorders and at the Department of Neurology of the TUM Klinikum Rechts der Isar in Munich, Germany.  Here he discusses the recent publication "Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-AL...

ALS Untangled Series Ep. 66 - PoNS 03.06.2026

Portable Neuromodulation Stimulator (PoNS) is a type of electrical stimulation that can theoretically increase rewiring in the brain (neuroplasticity).  Small trials suggest that it can improve walking in MS but thus far there are no data in people living with ALS.  Here we further discuss the mechanism, studies in other conditions, and potential risks.

ALS Untangled Series Ep. 65 - ISRIB 15.05.2026

ISRIB stands for “integrated stress response inhibitor).  As we discuss here, it is an oral medication that inhibits an intracellular pathway called the integrative stress response pathway.  It is not FDA approved for any condition but is available in Spain without a prescription.  There are theoretical ways that inhibiting this pathway could help a person with ALS, and there is promising data fro...

CReATe Author Series Ep. 18 - Dr. Michael Benatar on MMI as a prodromal stage of ALS 09.04.2026

Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “Proposed Research Criteria for Mild Motor Impairment as a Prodromal Syndrome in Amyotrophic Lateral Sclerosis." 

CReATe Author Series Ep. 17 - (AI generated) Podcast on C9orf72 Disease Prevention Trials 08.01.2026

Here we have a podcast produced by artificial intelligence discussing the recent publication “Design considerations for C9orf72 disease prevention trials”. 

ALS Untangled Series Ep. 64 - Wahls Protocol 10.12.2025

The Wahls Protocol is a diet that may reduce inflammation, oxidative stress, and mitochondrial dysfunction.  Although these are plausible mechanisms for slowing ALS progression, we discuss the fact that there are no actual data to support this hypothesis, and there are risks which are especially important to consider in people living with ALS.  

ALS Untangled Series Ep. 63 - Psilocybin 17.11.2025

Psilocybin is a psychedelic chemical derived from mushrooms.  It is under study for mood problems in people with ALS.  Here we review its plausible mechanisms for slowing ALS progression.  But there are no data from preclinical models, trials or case reports that currently support this benefit.  And there can be serious risks to using this chemical.

ALS Untangled Series Ep. 62 - Ashwagandha 20.10.2025

Here we review ashwagandha a nutritional supplement that has plausible mechanisms for slowing ALS, promising pre-clinical evidence, and a reasonable safety profile.  There is one person with ALS who experienced a reversal of symptoms on a cocktail of treatments that included ashwagandha.  Cases like this are difficult to interpret as there can be multiple explanations for a person experiencing an...

CReATe Author Series Ep. 16 - Dr. Johnathan Cooper-Knock on Exercise and ALS 24.09.2025

Dr. Johnathan Cooper-Knock is a neurologist and clinical lecturer at the University of Sheffield.  His research focuses on genetic causes of ALS.  Here he discusses his recent publication “Extreme exercise in males is linked to mTOR signalling and onset of amyotrophic lateral sclerosis”.

ALS Untangled Series Ep. 61 - Zinc 09.09.2025

Here we review Zinc supplements as a treatment for ALS.  These are inexpensive, reasonably safe at certain doses, and are easy to acquire.  They have plausible mechanisms by which they could slow ALS progression.  However, the data from people living with ALS is not very convincing yet.

CReATe Author Series Ep. 15 - Drs. Terry Heiman-Patterson and Michael Benatar on Clinical Guidance for ALS/FTD at-risk carriers 02.06.2025

Dr. Terry Heiman-Patterson is a neurologist and professor at Temple University and the director of the Center for Neurodegenerative Disorders and the MDA/ALS Center of Hope.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  In this podcast they will be discussing their recent publication “G...

CReATe Author Series Ep. 14 - Drs. Ruben van Eijk and Michael Benatar on Phase 2 Trials and ALS 01.05.2025

Dr. Ruben van Eijk is an associate professor in the Department of Neurology at the University Medical Center Utrecht in the Netherlands as well as a statistical consultant and medical statistician for the clinical trial methodology group at the Julius Center also in Utrecht.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS C...

CReATe Author Series Ep. 13 - Dr. Benatar on Prognostic Markers and ALS 18.02.2025

Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  Here he discusses the recent publication “Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis”.

CReATe Author Series Ep. 12 - Drs. Jesse Crayle and Evadnie Rampersaud on Genetics and ALS Reversal Phenotype 02.01.2025

Dr. Jesse Crayle is a clinical neuromuscular fellow in the Department of Neurology at Washington University in St. Louis and Dr. Evadnie Rampersaud is a Principal Bioinformatics Research Scientist at St. Jude Children’s Research Hospital.  They will be discussing their publication “Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.”

ALS Untangled Series Ep. 60 - Nuedexta 04.12.2024

Nuedexta is a combination of dextromethorphan and quinidine, and is FDA approved for treating “pseudobulbar affect” (a symptom complex where patients lose control of their laughing and crying).  Here we summarize recent trials suggesting that Nuedexta might also help bulbar function (speech, swallowing and oral secretions).  We also discuss important risks, monitoring, and insurance coverage.

ALS Untangled Series Ep. 59 - Lions Mane 04.11.2024

Lions Mane is a mushroom that has neuroprotective, neurotrophic, antioxidant, and anti-inflammatory properties.  Here we review what is known about its use in ALS models as well as patients living with the disease.

ALS Untangled Series Ep. 58 - Insulin 01.10.2024

Insulin is a hormone most commonly used to lower blood sugar in people with diabetes.  Here we talk about some theoretical ways it might help help people with ALS, as well as the lack of convincing case reports or trials and the risks.

ALS Untangled Series Ep. 57 - Caffeine 05.09.2024

Caffeine is a chemical most of us ingest every day.  In addition to its stimulant properties, there are some theoretical ways it could help slow ALS progression.  Here we discuss the contradictory pre-clinical models and the lack of a convincing relationship between caffeine intake and ALS progression in natural history studies.

CReATe Author Series Ep. 11 - Dr. Benatar and the Miami Framework for ALS 13.08.2024

Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology”. 

CReATe Author Series Ep. 10 - Drs. McHutchison and Benatar on Cognitive and Behavioral Changes in MND 15.02.2024

Dr. Caroline McHutchison is a Neuropsychologist and CReATe Clinical Research Scholar at the University of Edinburgh and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Temporal course of cognitive and behavioural changes in motor neuron dise...

CReATe Author Series Ep. 9 - Drs. Heatwole and Benatar on Patient Reported Outcome Measures and ALS 03.01.2024

Dr. Chad Heatwole is a Professor of Neurology and the Director of the Center for Health and Technology at the University of Rochester Medical Center and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “The amyotrophic lateral sclerosis-health...

ALS Untangled Series Ep. 56 - Sodium Chlorite 15.11.2023

Sodium chlorite is an experimental drug targeting macrophage activation. It exists in different formulations. An oral formulation has potentially deadly side effects. An IV formulation called NP001 has been in recent trials targeting a subset of people with ALS. Here we review the interesting development of this product and where we expect that to go in the near future.

Listen to the CReATe Podcast podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.